联合米托蒽醌治疗急性白血病的临床研究  

Application of Mitoxantrone in the Treatment of Acute Leukemia

作　　者：陈友华[1] 高清平[1] 谢燕[1] 李秀珍[1] 陈济民[1] 

机构地区：[1]武汉大学人民医院血液科,武汉430060

出　　处：《武汉大学学报（医学版）》2001年第1期53-54,57,共3页Medical Journal of Wuhan University

摘　　要：目的 :观察米托蒽醌治疗急性白血病的临床疗效和毒副作用。方法 :采用以米托蒽醌为主组成的联合化疗方案 ,治疗 5 7例 (初发 40例、复发 17例 )急性白血病。结果 :总有效率 82 .5 %。其中初治的 40例 ,完全缓解(CR) 2 7例 ,部分缓解 (PR) 8例 ,有效率 87.5 % ;对照组 35例初治的急性白血病 ,CR 14例 ,PR 7例 ,有效率 6 0 .0 %。两组比较差异有显著性 (P <0 .0 1)。复发 17例中CR 8例 ,PR 4例。米托蒽醌主要副作用表现为骨髓抑制。结论 :以米托蒽醌为主组成联合化疗方案治疗初发和复发的急性白血病具有较好的疗效 ,毒副作用小。Fifty seven patients with acute leukemia (AL) were treated by chemotherapy combined with mitoxantrone. There were 40 patients with initial AL and 17 patients with relapsed AL. The results showed that the total effective rate was 82.5%. There were 27 patients who achieved complete remission (CR) and 8 patients partial remission (PR) in 40 patients with initial AL, and the effective rate of 87.5% was significantly higher than that of 60.0% in control group (P< 0.01 ). There were 8 patients who achieved CR and 4 patients PR in 17 relapsed AL. The major side effect encountered was marrow suppression. It was concluded that mitoxantrone combined chemotherapy was favorable in the treatment of initial and relapsed AL.

关 键 词：米托蒽醌 急性白血病 药物联合治疗 毒副作用 

分 类 号：R733.71[医药卫生—肿瘤]